Establishment Labs Competitors

Establishment Labs (NASDAQ:ESTA) and MSA Safety (NYSE:MSA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for Establishment Labs and MSA Safety, as provided by MarketBeat.

Establishment Labs currently has a consensus target price of $41.40, suggesting a potential downside of 40.03%. MSA Safety has a consensus target price of $138.6667, suggesting a potential downside of 13.87%. Given MSA Safety's higher probable upside, analysts plainly believe MSA Safety is more favorable than Establishment Labs.

Institutional & Insider Ownership

54.8% of Establishment Labs shares are owned by institutional investors. Comparatively, 77.2% of MSA Safety shares are owned by institutional investors. 2.6% of Establishment Labs shares are owned by company insiders. Comparatively, 7.0% of MSA Safety shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Establishment Labs and MSA Safety's gross revenue, earnings per share and valuation.

MSA Safety has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than MSA Safety, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Establishment Labs and MSA Safety's net margins, return on equity and return on assets.

Risk and Volatility

Establishment Labs has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, MSA Safety has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.

Summary

MSA Safety beats Establishment Labs on 10 of the 14 factors compared between the two stocks.

Eargo (NASDAQ:EAR) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Eargo and Establishment Labs, as reported by MarketBeat.com.

Eargo currently has a consensus price target of $48.00, suggesting a potential downside of 17.82%. Establishment Labs has a consensus price target of $41.40, suggesting a potential downside of 40.03%. Given Eargo's stronger consensus rating and higher probable upside, analysts plainly believe Eargo is more favorable than Establishment Labs.

Profitability

This table compares Eargo and Establishment Labs' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Eargo and Establishment Labs' revenue, earnings per share and valuation.

Eargo has higher earnings, but lower revenue than Establishment Labs.

Institutional & Insider Ownership

54.8% of Establishment Labs shares are owned by institutional investors. 2.6% of Establishment Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Eargo beats Establishment Labs on 5 of the 8 factors compared between the two stocks.

Avanos Medical (NYSE:AVNS) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk and analyst recommendations.

Volatility & Risk

Avanos Medical has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Establishment Labs has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.

Earnings & Valuation

This table compares Avanos Medical and Establishment Labs' top-line revenue, earnings per share (EPS) and valuation.

Establishment Labs has lower revenue, but higher earnings than Avanos Medical. Establishment Labs is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Avanos Medical and Establishment Labs' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Avanos Medical and Establishment Labs, as provided by MarketBeat.com.

Avanos Medical currently has a consensus target price of $38.40, suggesting a potential downside of 16.49%. Establishment Labs has a consensus target price of $41.40, suggesting a potential downside of 40.03%. Given Avanos Medical's higher possible upside, research analysts clearly believe Avanos Medical is more favorable than Establishment Labs.

Institutional and Insider Ownership

94.8% of Avanos Medical shares are held by institutional investors. Comparatively, 54.8% of Establishment Labs shares are held by institutional investors. 1.5% of Avanos Medical shares are held by insiders. Comparatively, 2.6% of Establishment Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Avanos Medical beats Establishment Labs on 8 of the 14 factors compared between the two stocks.

Establishment Labs (NASDAQ:ESTA) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings and valuation.

Volatility & Risk

Establishment Labs has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.

Earnings and Valuation

This table compares Establishment Labs and Inogen's revenue, earnings per share (EPS) and valuation.

Inogen has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

54.8% of Establishment Labs shares are owned by institutional investors. Comparatively, 95.1% of Inogen shares are owned by institutional investors. 2.6% of Establishment Labs shares are owned by company insiders. Comparatively, 4.8% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Establishment Labs and Inogen's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for Establishment Labs and Inogen, as reported by MarketBeat.com.

Establishment Labs presently has a consensus price target of $41.40, indicating a potential downside of 40.03%. Inogen has a consensus price target of $63.00, indicating a potential upside of 20.02%. Given Inogen's higher probable upside, analysts clearly believe Inogen is more favorable than Establishment Labs.

Summary

Inogen beats Establishment Labs on 9 of the 14 factors compared between the two stocks.

Establishment Labs (NASDAQ:ESTA) and Sientra (NASDAQ:SIEN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Establishment Labs and Sientra, as reported by MarketBeat.

Establishment Labs presently has a consensus price target of $41.40, suggesting a potential downside of 40.03%. Sientra has a consensus price target of $8.20, suggesting a potential upside of 5.40%. Given Sientra's stronger consensus rating and higher probable upside, analysts plainly believe Sientra is more favorable than Establishment Labs.

Volatility & Risk

Establishment Labs has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Sientra has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500.

Profitability

This table compares Establishment Labs and Sientra's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Establishment Labs and Sientra's gross revenue, earnings per share (EPS) and valuation.

Establishment Labs has higher revenue and earnings than Sientra. Establishment Labs is trading at a lower price-to-earnings ratio than Sientra, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

54.8% of Establishment Labs shares are held by institutional investors. Comparatively, 71.0% of Sientra shares are held by institutional investors. 2.6% of Establishment Labs shares are held by insiders. Comparatively, 2.8% of Sientra shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Establishment Labs (NASDAQ:ESTA) and Invacare (NYSE:IVC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Profitability

This table compares Establishment Labs and Invacare's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Establishment Labs and Invacare, as reported by MarketBeat.

Establishment Labs currently has a consensus target price of $41.40, indicating a potential downside of 40.03%. Invacare has a consensus target price of $14.00, indicating a potential upside of 53.85%. Given Invacare's stronger consensus rating and higher probable upside, analysts plainly believe Invacare is more favorable than Establishment Labs.

Earnings & Valuation

This table compares Establishment Labs and Invacare's gross revenue, earnings per share and valuation.

Establishment Labs has higher earnings, but lower revenue than Invacare. Establishment Labs is trading at a lower price-to-earnings ratio than Invacare, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Establishment Labs has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Invacare has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Institutional & Insider Ownership

54.8% of Establishment Labs shares are held by institutional investors. Comparatively, 96.7% of Invacare shares are held by institutional investors. 2.6% of Establishment Labs shares are held by insiders. Comparatively, 3.2% of Invacare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Invacare beats Establishment Labs on 10 of the 14 factors compared between the two stocks.